Finance Watch: UroGen Accesses Cash After Phase III Bladder Cancer Success

SPACs Have More Mixed Results

Public Company Edition: UroGen raised $120m in a private placement of ordinary shares. Also, Verrica entered into a debt financing for up to $125m upon approval of Ycanth for molluscum contagiosum and job cuts were announced by Homology, Mersana, Infinity and others.

Finance Watch Public Company — • Source: Alamy

UroGen Pharma, Ltd. anticipated filing for US Food and Drug Administration approval in 2024 for UGN-102 in the treatment of low-grade, intermediate-risk, non-muscle invasive bladder cancer (LG-IR-NMIBC) based on positive results from the Phase III ATLAS and ENVISION clinical trials, and the company raised a $120m private placement of ordinary shares to fund its ongoing trials, filings and commercial efforts.

Princeton, NJ-based UroGen announced the Phase III results and its private placement of 12.58 million ordinary shares, or pre-funded warrants...